Biocon Biologics to Commercialize Biosimilar Aflibercept Worldwide After Settlement

Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced a new settlement and license agreement with Regeneron and Bayer for biosimilar Aflibercept (40mg/ml) in Europe and the rest of the world. This agreement allows Biocon Biologics to commercialize Yesafili®, a biosimilar Aflibercept (40mg/ml)), in all countries worldwide. The European Commission and the Medicines & Healthcare products Regulatory Agency have previously approved YESAFILI. The biosimilar is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). Biocon Biologics has a pipeline of 20+ biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases.